Evidence map›Paper›PMID 41636476›Full record

ArticleAntimicrobial agents and chemotherapy2026

The International Immunotherapy Society for Fungal Diseases.

Arturo Casadevall, Dimitrios P Kontoyiannis, Frank L van de Veerdonk

Abstract readEditorial
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Arturo Casadevall *Department of Molecular Microbiology and Immunology, Johns Hopkins School of Public Health, Baltimore, Maryland, USA.ORCID 0000-0002-9402-9167
Dimitrios P Kontoyiannis *Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-8051-2940
Frank L van de Veerdonk *Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The treatment of invasive fungal diseases is unsatisfactory because of high morbidity and mortality despite antifungal therapy. These patients are often immunocompromised, and improvements in treatment outcome are likely to require immune therapy. To promote immune therapies against fungal diseases, the International Immunotherapy Society for Fungal Diseases was organized.

Indexed as

ImmunotherapyInvasive Fungal InfectionsMycosesAntifungal AgentsHumansImmunocompromised HostAntifungal Agentsfungalimmunocompromisedimmunotherapy

Identifiers

PMID41636476
PMCPMC12959142

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.